Rigel's Final ARROW Clinical Trial Data Shows Promising Outcomes for GAVRETO® in RET+ NSCLC Patients Rigel Pharmaceuticals has published noteworthy final results from the ARROW clinical trial for GAVRETO®, highlighting its effectiveness in treating RET+ NSCLC patients.

Rigel's Final ARROW Clinical Trial Data Shows Promising Outcomes for GAVRETO® in RET+ NSCLC Patients #United_States #South_San_Francisco #Rigel_Pharmaceuticals #GAVRETO #RET_fusion-positive

Rigel Pharmaceuticals Reports Impressive Financial Results for 2025 with Robust Growth and A Promising Future Rigel Pharmaceuticals announces strong financial results for Q4 and FY 2025, highlighting significant growth in product sales and a positive outlook for 2026.

Rigel Pharmaceuticals Reports Impressive Financial Results for 2025 with Robust Growth and A Promising Future #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO

Rigel Pharmaceuticals Announces Positive 2025 Revenues and 2026 Projections Rigel Pharmaceuticals reveals a promising business update for 2025, highlighting substantial revenue growth and optimistic projections for continued expansion in 2026.

Rigel Pharmaceuticals Announces Positive 2025 Revenues and 2026 Projections #United_States #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO

Rigel Pharmaceuticals Announces Strong Financial Growth and Clinical Progress in Q2 2025 Rigel Pharmaceuticals reports impressive financial results for Q2 2025, with $101.7 million in total revenue and significant pipeline advancements in hematology and oncology.

Rigel Pharmaceuticals Announces Strong Financial Growth and Clinical Progress in Q2 2025 #United_States #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #GAVRETO

Rigel Pharmaceuticals to Present Key Data at ASCO and EHA 2025 Conferences Rigel Pharmaceuticals reveals upcoming poster presentations at the 2025 ASCO Annual Meeting and EHA Congress, showcasing vital data on treatments for cancer and blood disorders.

Rigel Pharmaceuticals to Present Key Data at ASCO and EHA 2025 Conferences #United_States #South_San_Francisco #Rigel_Pharmaceuticals #REZLIDHIA #GAVRETO